27LBA Evidence of activity of a new mechanism of action (MoA): A first-in-human study of the first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640, as monotherapy or in combination. Issue 3 (September 2015) - Arkenau, H.T.; Voskoboynik, M.; Infante, J.; Brenner, A.; Patel, M.; Borazanci, E.; Falchook, G.; Molife, L.R.; Pant, S.; Dean, E.; Pelosof, L.; Jones, S.; et al.